| Study | Exclusion reasons | Remarks | Reference(s) | ||
|---|---|---|---|---|---|
| Gilboa, 2021 | - |
Gilboa M J Infect Dis 2021 Nov 29;jiab584. 10.1093/infdis/jiab584 |
|||
| Danza, 2022 | case series | no control group | Omicron became the predominant SARS-CoV-2 variant in LAC during the week ending December 18, accounting for 57% of all sequenced specimens;Omicron prevalence continued to increase, accounting for 99% of all sequenced specimens for the week ending January 8, 2022 |
Danza P et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7105e1 |
|
| COV-BOOST, 2021 | randomized controlled trial | no clinically relevant endpoint | Phase 2 trial. |
Munro APS Lancet 2021 Dec 2;S0140-6736(21)02717-3. 10.1016/S0140-6736(21)02717-3 |
|
| Mattiuzzi, 2022 | - | other | same population alder study than mattiuzzi, 2022 |
Mattiuzzi C Eur Geriatr Med 2022 Jan 24. 10.1007/s41999-022-00615-7 |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
